Stockholm, November 14, 2023. Sigrid Therapeutics today announced that the company has launched Glucose Stabiliser in the US. The product is an over-the-counter dietary supplement for blood sugar control that reduces calorie intake from fat and carbohydrates. Sigrid’s strategic launch in the US market could not have come at a better time, with approximately 1 in 10 Americans facing a type 2 diagnosis at the same time as weight loss drugs are increasing in popularity among the general population.

The dietary supplement, which is taken before the two biggest meals of the day, is based on over 10 years of research. Sigrid’s co-founder, Professor Tore Bengtsson, discovered that undesirable changes in metabolism were normalized after the ingestion of modified silica particles. Silicon is 100% natural, and one of the most abundant elements on the planet.

Glucose Stabiliser is based on the patented SiPore® technology discovered in 2008. SiPore® has been shown to lower blood sugar, minimize gas and bloating, maintain fullness for longer, reduce appetite and thereby contribute to weight loss. Clinical research has shown that patients with type 2 diabetes who took SiPore® had a 40% greater reduction in HbA1c and also in half the treatment time compared to Metformin, one of the most widely used drugs.

The particles, which consist of micrometre-sized silica particles, exert their effect inside the stomach and are not absorbed into the bloodstream. The particles act as a molecular filter by mechanically protecting the food from the digestive enzymes. Because the latter break down complex carbohydrates and fats, digestion is slowed down. With a slower digestion process, those who use Glucose Stabiliser can expect to feel fuller for longer, lose weight, and achieve lower cholesterol levels while continuing to live their lives to the fullest without restrictions. Unlike many prescription diabetes medications with their long lists of side effects, Glucose Stabilizer is very well tolerated. With the SiPore® technology, you get a product that is generally recognized as safe (GRAS – Generally Regarded As Safe). The classification confirms its safety for use to promote a slower digestive process and weight control without imposing restrictions on daily life.

Although the importance in the diabetes field is primary, Glucose Stabiliser is also an excellent option for non-diabetics who are considering trying the new and popular prescription drugs for weight loss but are put off by the cost and/or injections. Glucose Stabiliser is administered orally and stays in the stomach and by acting in a similar way but without the side effects associated with drugs that reach the bloodstream, the product is a suitable option for those seeking general well-being and weight loss. In addition, the product is the perfect solution for those who are worried about weight gain after stopping the new drugs.

“Glucose Stabiliser is a testament to Sigrid’s mission to help people optimize their metabolism in an affordable and accessible way,” said Sana Alajmovic, CEO of Sigrid Therapeutics. “I’ve seen my dad develop type 2 diabetes after struggling to control his blood sugar for a long time. For me, therefore, it is as much a personal calling as it is a professional mission to develop innovative treatments that enable users to continue living their lives to the fullest without having to drastically change their lifestyle.”

For more information, www.sigridthx.com, or please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396
Email: sana@sigridthx.com

The price for Glucose Stabilizer starts at $99 per bottle and can now be purchased online at https://sigridstabiliser.com/. Glucose Stabiliser will be launched in a limited edition in Sweden during the autumn.

About Sigrid Therapeutics
Sigrid Therapeutics is a Swedish biotech company dedicated to revolutionizing the management of obesity and diabetes through its innovative SiPore® technology. The company’s flagship product, SiPore21®, which offers a natural, non-drug solution for prediabetes progression and weight management, is currently being tested in a clinical trial called SHINE. With a focus on impactful innovation, Sigrid Therapeutics is committed to improving the well-being of individuals worldwide. For more information, please visit https://sigridstabiliser.com/.